NASDAQ OMX

Aino Health AB (publ): The Offer in Aino Health AB (publ) heavily oversubscribed

Dela

PRESS RELEASE
December 9, 2016

NOT FOR DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, TO NEWS DISTRIBUTORS IN THE UNITED STATES, OR FOR DISTRIBUTION IN OR INTO THE UNITED STATES, AUSTRALIA, HONG KONG, JAPAN, CANADA, NEW ZEALAND, SINGAPORE, SOUTH AFRICA OR ANY OTHER JURISDICTION WHERE SUCH DISTRIBUTION OR PUBLICATION WOULD NOT BE ALLOWED BY APPLICABLE LAW.
  
Aino Health AB (publ) ("Aino Health" or the "Company") has completed the Offer to the market to subscribe for shares in the Company for a total of 53.8 MSEK (the "Offer"), distributed on a share issue of 46.8 MSEK (the "Share Issue") and an Over-allotment of existing shares of 7.0 MSEK for stabilization activities (the "Over-allotment"). The Over-allotment including stabilization of the share price during 30 calendar days may imply that Aino Health will receive an addition of 7.0 MSEK through a share issue included in the Over-allotment option directed to Erik Penser Bank AB, after which the Company would receive up to 48.8 MSEK.  

The Offer attracted strong interest and was subscribed to about 206 percent, equivalent to 2.1 times the Offer. Due to the strong interest shares have been allocated to around 1 100 new shareholders among almost 4 000 applicants. First day of trading Aino Health's shares is scheduled for Friday December 16, 2016.

November 27, 2016, the Board of Directors in Aino Health published the decision to apply for listing of the Company's shares on Nasdaq First North, and in connection with the listing the Board of Directors decided to diversify the ownership through a Share Issue according to the Offer. The Offer consists of 1,800,000 newly issued shares and an Over-allotment of 270,000 existing shares as a part of the stabilization of the share price during 30 calendar days. The Company may receive an addition of 270,000 shares through the Over-allotment option directed to Erik Penser Bank as a part of the agreed stabilization of the share price.

The number of shares will increase from 3,622,770 to 5,422,770 through the Share Issue and up to 5,692,770 shares if the Over-allotment is fully exercised. The dilution for existing shareholders amounts to 33.2 percent and to a maximum of 36.2 percent if the Over-allotment option is fully exercised.

The Offer implies that the Company will be added around 1 100 new shareholders, after which the total number of shareholders will amount to approximately 1 200. The Company will meet the share distribution requirements on Nasdaq First North and the first day of trading is scheduled for Friday December 16, 2016.

The subscription period for the Offer expired on Thursday, December 8, 2016. A number of institutional partners and private investors have, before the initiated subscription period, undertaken to subscribe for shares in the Share Issue corresponding to approximately 31.9 MSEK, or about 86 percent of the Share Issue.

The Board of Directors in Aino Health has, in consultation with Erik Penser Bank, decided on the allotment of shares in the Offer, in which the objective has been to achieve a good distribution of the share to enable a regular and liquid trading on Nasdaq First North as well as achieving a desired strategic ownership base. The allotment decision will be obtained in the form of a contract note. Information will not be sent to those who have not been allotted shares.

After the Offer has been registered at the Swedish Companies Registration Office the total number of shares in Aino Health will increase by 1,800,000 shares from 3,622,770 shares to 5,422,770 shares. The share capital will increase by 4,500,000 SEK to 13,556,925 SEK. If the Over-allotment option is fully exercised, this implies an additional increase of 270,000 shares and an increase of the share capital of 675,000 SEK to 14,231,925 SEK.

"We are very pleased with the great interest we have had in Aino Health's IPO. While we have secured capital for our expansion into Europe with focus on Sweden and Germany as the first countries, we have received a large number of new shareholders. We are very happy for this and the legitimacy that our listing gives in various customer contacts", says Jyrki Eklund, CEO of Aino Health

Advisers
Erik Penser AB is the financial advisor and Advokatfirman Lindahl KB is the legal adviser in the Offer and listing on Nasdaq First North. Erik Penser AB is Certified Adviser to the Company.

Important information
Publication and distribution of this press release may in certain jurisdictions be restricted by law and persons in those jurisdictions where this press release has been published or distributed should inform themselves about and follow such restrictions. The information in this press release is not an offer to acquire, subscribe for or otherwise trade in shares or another security in Aino Health.

This press release may not be released, published or distributed, directly or indirectly, in or into the United States, Australia, Hong Kong, Japan, Canada, New Zealand, Singapore, South Africa or another country where such action requires further measures in addition to what follows from Swedish law or where this would contravene with laws or regulations of that country. The information in this press release may not be forwarded, reproduced or disclosed in ways that conflict with such restrictions. Omission to follow this instruction may constitute a violation of the United States Securities Act of 1933 (the "Securities Act") in its present terms or applicable laws in other jurisdictions.

This information is such information that Aino Health AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at December 9 CET on 8:30 2016.

F or more information, please contact:
Jyrki Eklund, CEO
Phone: +358 40 042 4221
E-mail: jyrki.eklund@ainohealth.com

Cecilia Hollerup, Chairman of the Board of Directors
Phone: +46 70 829 33 36
E-mail: cecilia.hollerup@holleruppartners.se

About Aino Health
Aino Health operates within Corporate Health Management. The company has developed a complete system of IT-based services with a focus to improve corporate health and reduce sickness absence levels in private and public organizations.




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Aino Health AB (publ) via Globenewswire

Om

NASDAQ OMX
NASDAQ OMX



Följ NASDAQ OMX

Skriv in din e-postadress så får du ett mejl när vi har något nytt att berätta.

Senaste pressmeddelandena från NASDAQ OMX

Corporate R&D spending hits record highs for the Top 1000, despite concerns of economic protectionism24.10.2017 08:00Pressmeddelande

Annual worldwide R&D spending breaks through $700bn for the top 1000 corporate R&D spenders for first time 25% of executives surveyed reported having already experienced some pressure to change how or where they conduct innovation Amazon is the world's largest corporate spender on R&D at over $16bn Alphabet surpasses Apple, according to a global survey of R&D executives, as the Most Innovative Company and for the first time a Chinese company, Alibaba joins the Top 10 Most Innovative Companies list NEW YORK, Oct. 24, 2017 (GLOBE NEWSWIRE) -- Annual worldwide corporate R&D spending broke through $700bn in annual investment, according to an annual analysis of R&D spending across 1000 global public companies by P

TEAM Industries Announces New Innovative Transmission Incorporating Fallbrook's NuVinci® CVP Technology24.10.2017 02:25Pressmeddelande

Design is ready for vehicle implementation in powered recreational and utility vehicles CEDAR PARK, TEXAS and BAGLEY, MINNESOTA, Oct. 23, 2017 (GLOBE NEWSWIRE) -- TEAM Industries (TEAM) and Fallbrook Technologies Inc. (Fallbrook) announced today that TEAM has a production-ready innovative new transmission design for all-terrain vehicles (ATV) and utility task vehicles (UTV) available to OEMs for vehicle implementation. The transmission incorporates Fallbrook's NuVinci® continuously variable planetary (CVP) technology. NuVinci is a platform technology for a new class of continuously variable transmissions (CVT). It utilizes spheres instead of gears or belts, and can be deployed in a wide variety of applications to improve performance and/or system efficiency. TEAM has an exclusive licensing agreement with Fallbrook for the use of NuVinci CVP technology in North America and Europe in electric and gasoline light vehicle applications. TEAM is also workin

Telix Pharmaceuticals Limited Launches $50 Million Underwritten Initial Public Offering (ASX: TLX)23.10.2017 23:00Pressmeddelande

MELBOURNE, Australia, Oct. 23, 2017 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (Telix, the Company), an Australian biopharmaceutical company focused on the development of diagnostic and therapeutic products based on targeted radiopharmaceuticals or "molecularly-targeted radiation" (MTR), is pleased to announce the opening of its Initial Public Offering (IPO or Offer) to raise A$50 million. The IPO is an offer by Telix for the issue of 77.0 million shares at $0.65 per share and is fully underwritten by the Lead Managers, Taylor Collison Limited and Wilsons Corporate Finance Limited. The IPO has been strongly supported by the Company's existing shareholders, which include both industry partners and domestic institutional investors, such as Acorn Capital, CVC, Monash Investors, Viburnum Funds, Allan Moss and Alium Capital Management. With this Offer, Telix will further strengthen its Australian and international institutional shareholder base, including the addition of Fidel

Brookfield Asset Management Notice of 2017 Q3 Results Conference Call and Webcast23.10.2017 17:03Pressmeddelande

Date:    Thursday, November 9, 2017 Time:   11:00 a.m. (Eastern Time)  BROOKFIELD, News, Oct. 23, 2017 (GLOBE NEWSWIRE) -- You are invited to participate in Brookfield Asset Management's 2017 Third Quarter Conference Call & Webcast on Thursday, November 9, 2017 at 11:00 a.m. (Eastern Time) to discuss with members of senior management our results and current business initiatives. These results will be released on November 9th before 7:00 a.m. (Eastern Time) and will be available following the release on our website at www.brookfield.com "News - Press Releases." The Conference Call will also be Webcast live on our website, where it will be archived for future reference. To participate in the Conference Call, please dial 1-800-319-4610 toll free in North America, or for overseas calls please dial 1-604-638-5340 at approximately 10:50 a.m. The Conference Call will also be Webcast live at http://servic

Rapid Micro Biosystems Awarded a Contract by Biomedical Advanced Research and Development Authority (BARDA) for the Implementation of a Rapid Sterility Test for Vaccines23.10.2017 13:00Pressmeddelande

LOWELL, Mass., Oct. 23, 2017 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, a leading provider of automated, non-destructive, rapid microbial detection, is pleased to announce the receipt of a $7.3 million contract from the Biomedical Advanced Research and Development Authority (BARDA) for the implementation of a rapid sterility test for vaccines. This awarded grant is part of BARDA's Advance Development of Medical Countermeasures for Pandemic Influenza, which focuses on improving the government's responsiveness to future pandemic threats. When combined with Rapid Micro Biosystems' automated Growth Direct(TM) detection system, the rapid sterility test will result in faster release of vaccines and other sterile products. Timely delivery of these products carries multiple public benefits, principally in facilitating rapid responses to pandemic or emerging infections, agents of bioterrorism, and availability of life saving medicines. "Our continuing relationship with BARDA demonstrate

Xehar Fashion App Ditches the Shopping Cart and Picks Up Speed23.10.2017 12:00Pressmeddelande

New fast fashion app will shorten the checkout time by removing the shopping cart altogether. PLAYA VISTA, Calif., Oct. 23, 2017 (GLOBE NEWSWIRE) -- Fashion tech company Xehar, today announces they will be removing the shopping cart from their Xehar shopping app. For millennial women shoppers who are interested in fashion but are frustrated with the online shopping experience, the Xehar app is their solution. "Xehar has found a way to increase conversion for app purchases by simply removing the function of the shopping cart," says Hadari Oshri, founder and CEO of Xehar. "Within the app, users select complete outfits and purchase with ease. By removing the shopping cart we are reducing friction and speeding up the checkout process." A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/c58ce496-70e7-4675-8f59-3e39725708c4 Website and app owners deal with the reality of shopping cart abandonment

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum